You are here: Industry Insights > Pfizer

News List

Racing with Merck, Pfizer wins FDA 'breakthrough' tag for 20-valent pneumococcal vaccine fiercepharma
November 09, 2018
Pfizer and Merck are racing to the market with their next-gen pneumococcal candidates, and on Thursday, Pfizer's program got a major boost. The FDA granted the ...
Pfizer snags OK for Xalkori follow-up Lorbrena in its 3rd cancer approval in 2 months fiercepharma
November 06, 2018
Pfizer’s oncology unit is on a roll. On Friday, the FDA approved its third cancer-fighter from the New York drugmaker in the past two months, setting it up to mount a double-barreled challenge in ALK-positive non-small cell lung cancer.
Big Pharma rivals Pfizer and Novartis team up on NASH combo targets pharmatimes
November 02, 2018
Pfizer is joining forces with Novartis with a throw it all at the wall and see what sticks approach as they look to combine NASH assets to see if it can beat out liver fat, and get a slice of a
Pfizer and Novartis partner up to develop combo therapies for NASH pharmafile
October 31, 2018
Pfizer and Novartis are set to team up in a non-exclusive partnership aimed at the clinical development of one or more combo therapies for the treatment of non-alcoholic steatohepatitis (NASH).
Pfizer Q3 results: growth in revenue and income led innovative health segment pharmaceutical-technology
October 31, 2018
Pfizer has reported a 1% or $130m growth in revenue for the third quarter (Q3) 2018 to $13.3bn, compared to Q3 2017.
Novartis, Pfizer Partner for NASH contractpharma
October 30, 2018
Novartis, Pfizer Partner for NASH
Novartis Announces Clinical Collaboration with Pfizer americanpharmaceuticalreview
October 30, 2018
Novartis Announces Clinical Collaboration with Pfizer
Novartis, Pfizer join forces on potentially lucrative fatty liver disease expressbpd
October 30, 2018
The collaboration will help develop combination therapies involving medicines they have been working on separately to treat non-alcoholic steatohepatitis, or NASH
Pfizer & Lilly's non-opioid drug reduces pain in osteoarthritis pharmafile
October 25, 2018
Pfizer and Eli Lilly have announced data revealing that their nerve growth factor (NGF) inhibitor tanezumab met all three of its co-primary endpoints in the treatment of osteoarthritis (OA).
Pfizer, Eli Lilly report detailed results from late-stage study of NGF inhibitor tanezumab in osteoarthritis pain firstwordpharma
October 25, 2018
Pfizer, Eli Lilly report detailed results from late-stage study of NGF inhibitor tanezumab in osteoarthritis pain

Previous page 1 2 3 4 5 6 7 8 9 10 ... 83 84 Next page